US 12,186,407 B2
Formulations for small intestinal delivery of RSV and norovirus antigens
George Trager, Redwood City, CA (US); Sean Tucker, San Francisco, CA (US); Leesun Kim, Pacifica, CA (US); and Ciaran Scallan, San Francisco, CA (US)
Assigned to Vaxart, Inc., South San Francisco, CA (US)
Filed by Vaxart, Inc., South San Francisco, CA (US)
Filed on Aug. 2, 2022, as Appl. No. 17/816,788.
Application 17/816,788 is a continuation of application No. 15/580,651, granted, now 11,433,146, previously published as PCT/US2016/036461, filed on Jun. 8, 2016.
Claims priority of provisional application 62/175,081, filed on Jun. 12, 2015.
Prior Publication US 2022/0378944 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 48/00 (2006.01)
CPC A61K 48/0058 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2813 (2013.01); A61K 9/282 (2013.01); A61K 9/2846 (2013.01); A61K 39/12 (2013.01); C12N 2710/10341 (2013.01); C12N 2710/10343 (2013.01); C12N 2760/18534 (2013.01); C12N 2770/16034 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method for eliciting an immune response to a norovirus viral protein 1 (VP1) in a human, the method comprising administering an immunogenic composition to the human, wherein the immunogenic composition comprises an expression vector comprising a heterologous nucleic acid encoding a VP1 polypeptide, wherein the heterologous nucleic acid has at least 90% identity to SEQ ID NO:3 or at least 90% identity to SEQ ID NO:1.